All In Biotech

NDA 219301 · Kalvista

Ekterly

Sebetralstat · Oral · Plasma Kallikrein Inhibitor

NovelOrphan

CDER novel approval, Jul 3, 2025: To treat acute attacks of hereditary angioedema

Last checked: Nov 20, 2026Latest source record: Jul 3, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Jul 3, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

7

4 Phase 3, 1 recruiting

FAERS reports

539

191 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 1, 2026.

EKTERLY® is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. EKTERLY ® is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ( 1 )

Mechanism: Sebetralstat is a competitive, reversible inhibitor of plasma kallikrein. Plasma kallikrein is a serine protease that cleaves high molecular weight kininogen (HK) releasing bradykinin which increases vascular permeability through activation of bradykinin receptors causing edema. Sebetralstat inhibits the cleavage of HK and reduces production of bradykinin, thereby treating the clinical symptoms of an acute, episodic attack of HAE. Sebetralstat also inhibits the positive feedback mechanism of the kallikrein kinin system by plasma kallikrein, thereby reducing factor XIIa and additional plasma...

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 3, 2025 Original approval · Type 1 - New Molecular Entity NovelOrphanLetterLabelReview
1 products under this application
  • EKTERLY · SEBETRALSTAT 300MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sebetralstat" as an intervention, any sponsor and status, largest first.

All 7 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hereditary angioedema218
  • drug ineffective102
  • incorrect dose administered47
  • headache36
  • stress30
  • product dose omission issue22
  • weight increased22
  • weight decreased19
  • vomiting18
  • nausea15
  • off label use14
  • dizziness13

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20211
20222
20233
20248
202582
2026443

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6 on PubMed

Sponsor: Kalvista

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.